Market Research Report
HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal
|Published by||GlobalData||Product code||923903|
|Published||Content info||63 Pages
Delivery time: 1-2 business days
|HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal|
|Published: December 31, 2019||Content info: 63 Pages||
Human immunodeficiency virus (HIV) is a chronic disease that can be transmitted through blood, semen, and other bodily fluids by means such as sexual contact, pregnancy and breastfeeding, the sharing of injection drug equipment, and blood transfusions.
As the disease progresses, the virus causes depletion of a type of immune cell known as cluster of differentiation 4 (CD4) cells in the infected host. The loss of these cells leads to the progressive deterioration of the immune system, eventually resulting in the development of acquired immunodeficiency syndrome (AIDS), which is associated with multiple opportunistic infections.
Without treatment, HIV can progress to AIDS and may be fatal within a number of years. However, when appropriately managed with antiretroviral therapy (ART), HIV patients can achieve a near-normal life-expectancy.
Despite this, there is a continuing need to develop innovative new therapies for HIV, particularly among highly treated patients in whom HIV has developed resistance to one or more drugs.